Neuland Laboratories Ltd. (NEULANDLAB) AI Stock Analysis

5 Followers

Neuland Laboratories Ltd.

(NSE:NEULANDLAB)

Select Model

Rating:71Outperform

Price Target:INR 23,113.00▲(10.50% Upside)

Action:reiterated

Date:08/19/26

The overall score is driven primarily by Neuland Laboratories’ strong growth, solid profitability, and robust balance sheet, which together justify a high financial performance rating, but it is moderated by volatile and recently weak free cash flow, a rich valuation with a high P/E and minimal yield, and technical indicators showing a strong yet extended uptrend that raises near-term risk.

Positive Factors

Strong Revenue GrowthThe reported revenue growth indicates strong expansion in customer demand and commercial activity. If sustained, this scale can support operating leverage, strengthen Neuland’s position with global pharmaceutical customers, and provide a durable base for continued earnings growth.

Negative Factors

Negative Free Cash FlowNegative free cash flow means reported profits were not fully converted into funds available after investment and operating needs. If this persists, Neuland may have less flexibility to fund expansion internally, absorb volatility, or return capital while maintaining its growth plans.

Neuland Laboratories Ltd. (NEULANDLAB) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 271.12B
Dividend Yield: 0.16%
Average Volume (3M): 3,293
Price to Earnings (P/E): 59.3
Beta (1Y): 1.00
Revenue Growth: 50.46%
EPS Growth: 88.44%
Country: India
Employees: 1,643
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Neuland Laboratories Ltd. Business Overview & Revenue Model

Company Description

Neuland Laboratories Ltd. operates as a global developer and supplier of active pharmaceutical ingredients (APIs), distributing its products across India, Europe, the United States, and other international markets. These APIs are crucial components i...

Neuland Laboratories Ltd. Financial Statement Overview

Summary

Strong revenue and profit growth, solid margins, and a well-capitalized, low-leverage balance sheet support a high score, partially tempered by volatile and recently weak free cash flow that adds execution and funding risk.

Income Statement

82Very Positive

Balance Sheet

88Very Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	23.72B	20.23B	14.34B	15.16B	11.61B	9.23B
Gross Profit	11.85B	6.43B	6.84B	7.82B	5.47B	3.70B
EBITDA	7.94B	6.05B	4.18B	4.72B	2.79B	1.41B
Net Income	4.98B	3.64B	2.60B	3.00B	1.64B	638.22M
Balance Sheet
Total Assets	0	29.30B	21.80B	18.33B	15.80B	13.83B
Cash, Cash Equivalents and Short-Term Investments	766.70M	3.55B	3.67B	1.03B	454.16M	84.68M
Total Debt	0	3.01B	1.57B	953.90M	1.28B	2.41B
Total Liabilities	-18.74B	10.56B	6.55B	5.50B	5.86B	5.43B
Stockholders Equity	18.74B	18.74B	15.25B	12.83B	9.94B	8.41B
Cash Flow
Free Cash Flow	-2.07B	-588.87M	1.11B	1.18B	1.71B	-372.97M
Operating Cash Flow	-367.47M	3.38B	3.17B	2.61B	2.37B	603.89M
Investing Cash Flow	-521.95M	-4.32B	-2.98B	-1.50B	-614.99M	-955.16M
Financing Cash Flow	-19.30M	380.18M	249.61M	-692.82M	-1.36B	377.21M

Neuland Laboratories Ltd. Technical Analysis

Technical Analysis SentimentPositive

Last Price20916.60

Price Trends

50DMA21216.25Negative

100DMA20717.97Positive

200DMA17602.88Positive

Market Momentum

MACD-203.33Negative

RSI58.85Neutral

STOCH77.68Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NEULANDLAB, the sentiment is Positive. The current price of 20916.60 is above the 20-day moving average (MA) of 19639.44, below the 50-day MA of 21216.25, and above the 200-day MA of 17602.88, indicating a neutral trend. The MACD of -203.33 indicates Negative momentum. The RSI at 58.85 is Neutral, neither overbought nor oversold. The STOCH value of 77.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:NEULANDLAB.

Neuland Laboratories Ltd. Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:NEULANDLAB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ALIVUS	76Outperform	INR 178.72B	26.47	―	0.35%	8.19%	26.12%
IN:DIVISLAB	74Outperform	INR 3.00T	90.63	―	0.26%	21.56%	35.33%
IN:GRANULES	72Outperform	INR 198.14B	29.08	―	0.21%	21.75%	36.70%
IN:NEULANDLAB	71Outperform	INR 259.23B	59.32	―	0.16%	50.46%	88.44%
IN:AUROPHARMA	64Neutral	INR 1.05T	26.21	―	0.39%	13.53%	17.04%
IN:LAURUSLABS	63Neutral	INR 1.32T	96.73	―	0.09%	23.03%	95.69%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:NEULANDLAB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:NEULANDLAB	Neuland Laboratories Ltd.	20916.60	3492.26	20.04%
IN:AUROPHARMA	Aurobindo Pharma Ltd	1805.00	587.72	48.28%
IN:DIVISLAB	Divi's Laboratories Limited	11450.00	4965.35	76.57%
IN:ALIVUS	Glenmark Life Sciences Limited	1443.30	542.17	60.17%
IN:GRANULES	Granules India Limited	840.85	295.04	54.05%
IN:LAURUSLABS	Laurus Labs Ltd.	2395.10	1398.67	140.37%

Neuland Laboratories Ltd. Corporate Events

Neuland Laboratories Opens Special Window for Dematerialization of Physical Shares

Oct 24, 2026

Neuland Laboratories Ltd. has notified the stock exchanges that it has published newspaper advertisements announcing the opening of a special window for the transfer and dematerialization of physical shares. The move, undertaken in line with a recent...

Neuland Unit 3 Inspection Closed After U.S. FDA Issues EIR

Oct 14, 2026

Neuland Laboratories Ltd. has announced that the U.S. Food and Drug Administration has issued an Establishment Inspection Report for its Unit 3 manufacturing facility in Gaddapotharam Village, Sangareddy District. The report follows an inspection con...

Neuland Labs Opens Special Window for Demat of Physical Shares

Aug 23, 2026

Neuland Laboratories Ltd. has notified stock exchanges that it has published newspaper advertisements about the opening of a Special Window for the transfer and dematerialization of physical share certificates. The move, undertaken in line with a rec...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026

Neuland Laboratories Ltd. AI Stock Analysis